Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, ...

This was the stock's fourth consecutive day of gains.

Analyst Ratings Published 05/30/2025, 01:24 PM 0 RBC Capital cuts Regeneron stock rating, slashes target to $662 REGN 2.37% ...

On Wednesday, Citi analyst Geoff Meacham upgraded shares of Regeneron (NASDAQ: REGN) Pharmaceuticals from Neutral to Buy and increased the price target to $700 from $600.

On Wednesday, TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 from the previous $1,230. Despite the reduction, the firm ...

Investing.com - TD Cowen has reiterated a Buy rating and $800.00 price target on Regeneron Pharmaceuticals (NASDAQ:REGN), a prominent biotech player with a $58.1 billion market cap, following FDA ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?